I. Ketikoglou

发表

Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection

A. Hatzakis, G. Touloumi, V. Sypsa, 2004, Journal of viral hepatitis.

Association of antiviral therapy with reduced disease progression in chronic Hepatitis B patients: Results from a nation-wide cohort study.

G. Touloumi, G. Kitis, G. Dalekos, 2016, Hippokratia.

Circulating autoantibodies to endogenous erythropoietin are associated with chronic hepatitis C virus infection-related anemia.

N. Sipsas, D. Ziogas, C. Oikonomou, 2017, Hepatobiliary & pancreatic diseases international : HBPD INT.

A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1

A. Hatzakis, S. Manolakopoulos, T. Vassiliadis, 2003, Journal of viral hepatitis.

Predictors of sustained virological response in Greek and Egyptian patients with hepatitis C genotype 4: Does ethnicity matter?

D. Dimitroulopoulos, V. Papastergiou, L. Skorda, 2012, Journal of medical virology.

Serum procalcitonin levels in chronic hepatitis C patients under pegylated interferon-alpha plus ribavirin treatment.

N. Scarmeas, K. Pantazis, I. Elefsiniotis, 2006, Journal of Clinical Virology.

Hepatocellular carcinoma risk in HBeAg‐negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort

G. Touloumi, A. Ilias, G. Papatheodoridis, 2015, Journal of viral hepatitis.

Relationship between serum b2-microglobulin levels and virological breakthrough in HBeAg-negative chronic hepatitis B patients, under long-term treatment schedules including lamivudine.

K. Pantazis, I. Elefsiniotis, I. Glynou, 2005, World journal of gastroenterology.

Plasma pituitary adenylate cyclase activating polypeptide (PACAP) levels in chronic hepatitis B patients under lamivudine treatment

C. Mavrogiannis, K. Pantazis, I. Elefsiniotis, 2003, European journal of gastroenterology & hepatology.

Impact of interferon‐alpha therapy on liver fibrosis progression in patients with HBeAg‐negative chronic hepatitis B

E. Cholongitas, K. Petraki, I. Ketikoglou, 2005, Journal of viral hepatitis.

Long‐term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg‐negative chronic hepatitis B patients

G. Papatheodoridis, M. Deutsch, S. Manolakopoulos, 2011, Liver international : official journal of the International Association for the Study of the Liver.

Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study

G. Touloumi, C. Gogos, G. Papatheodoridis, 2011, Gut.

A viral kinetic study using pegylated interferon alpha 2b and lamivudine in naive patients with HBeAg(−)/I-BV-DNA(+) chronic hepatitis B: preliminary results

A. Hatzakis, K. Mimidis, D. Paraskevis, 2002 .

Hepatitis C virus survival curve analysis in naïve patients treated with peginterferon alpha-2b plus ribavirin. A randomized controlled trial for induction with high doses of peginterferon and predictability of sustained viral response from early virologic data.

K. Mimidis, I. Elefsiniotis, A. Protopapas, 2006, Journal of gastrointestinal and liver diseases : JGLD.

Pegylated interferon alfa-2b pen device and ribavirin treatment for patients with chronic hepatitis C: an evaluation of patient satisfaction

J. Kountouras, K. Mimidis, D. Dimitroulopoulos, 2010, European journal of gastroenterology & hepatology.

Hepatitis C virus genotyping in Greece: Unexpected high prevalence of genotype 5a in a Greek island

I. Goulis, V. Papastergiou, L. Skorda, 2012, Journal of medical virology.

The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha‐2b plus ribavirin treatment of naïve and nonresponder chronic hepatitis C patients

L. Sidiropoulos, I. Vafiadi, G. Hatzis, 2005, Journal of viral hepatitis.

Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study.

Christos G Gogos, G. Touloumi, G. Papatheodoridis, 2014, Hippokratia.

Serological profile of HBV infection and liver histopathology among injecting drug users with chronic HCV infection in Greece.

N. Fotos, K. Pantazis, I. Elefsiniotis, 2005, European journal of internal medicine.

Future trends of HCV‐related cirrhosis and hepatocellular carcinoma under the currently available treatments

A. Hatzakis, G. Touloumi, V. Sypsa, 2005 .

Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype‐specific incidence and molecular characterization of genotype 4 isolates

G. Magiorkinis, A. Hatzakis, G. Kitis, 2006, Journal of viral hepatitis.

A randomized trial to assess the efficacy of interferon‐alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C

A. Hatzakis, L. Sidiropoulos, V. Sypsa, 2003, Journal of viral hepatitis.

Immunogenicity of recombinant hepatitis B vaccine in treatment-naive and treatment-experienced chronic hepatitis C patients: the effect of pegylated interferon plus ribavirin treatment.

K. Kamposioras, K. Pantazis, I. Elefsiniotis, 2006, World journal of gastroenterology.

Hepatic parenchyma resection using stapling devices: peri-operative and long-term outcome.

C. Dervenis, P. Papakostas, I. Ketikoglou, 2009, HPB : the official journal of the International Hepato Pancreato Biliary Association.

Changing serological status and low vaccination-induced protection rates against hepatitis B characterize chronic hepatitis C virus-infected injecting drug users in Greece: need for immunization policy

K. Pantazis, I. Elefsiniotis, E. Tsianos, 2006, European journal of gastroenterology & hepatology.

Cirrhosis but not neutropenia is associated with the development of infection in patients with chronic hepatitis C undergoing treatment with pegylated interferon‐alpha and ribavirin

D. Pectasides, M. Deutsch, S. Manolakopoulos, 2014, Journal of viral hepatitis.

Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin.

N. Scarmeas, K. Pantazis, I. Elefsiniotis, 2008, European journal of internal medicine.

Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments.

A. Hatzakis, G. Touloumi, V. Sypsa, 2004, Journal of viral hepatitis.

G. Touloumi, C. Gogos, G. Papatheodoridis, 2011, Gut.